Stabilized amphotericin B nanoparticles for treating vaginal yeast infections
Innovative nanoparticle formulation of Amphotericin B for prolonged stability and enhanced treatment of azole-resistant vaginal yeast infections. These stabilized particles enable localized administration, overcoming traditional solubility and toxicity challenges.
Overview
Luna Labs presents a groundbreaking approach to treating recurrent vaginal yeast infections with stabilized Amphotericin B (AmpB) nanoparticles. This innovative formulation addresses the growing issue of azole-resistant Candida infections by localizing treatment, improving drug stability, and minimizing systemic toxicity. By encapsulating AmpB in solid lipid nanoparticles, the formulation retains antifungal efficacy for up to 14 weeks in aqueous media, providing a reliable alternative to traditional intravenous administration.
Technical specifications
Key features:
- Stabilization of Amphotericin B in solid lipid nanoparticles, enhancing aqueous solubility and stability.
- Demonstrated antifungal activity against Candida albicans persisting for at least 14 weeks.
- Potential inclusion of mucoadhesive coatings to improve tissue permeation and residence time.
- Designed for localized treatment, reducing systemic exposure and possible toxicity.
Technology readiness level
This solution is currently at Technology Readiness Level 4, indicating that it has been validated in laboratory conditions. Future steps include efficacy testing in animal models for vaginal yeast infections and safety evaluations to determine potential over-the-counter availability.
About Luna Labs
Luna Labs is a product development company based in Charlottesville, Virginia, that creates specialized solutions for the defense, industrial, and healthcare sectors. The company leverages a multidisciplinary approach combining materials science, biotechnology, and systems engineering to solve complex technical challenges. By repurposing advanced technologies—such as adapting sol-gel chemistry for corrosion prevention or mimicking viral structures for drug delivery—Luna Labs develops breakthrough innovations. Their diverse portfolio includes advanced protective coatings, real-time asset monitoring systems, medical simulation training tools, and drug delivery platforms designed to improve human performance and safeguard critical infrastructure.
These technologies address significant real-world problems, such as enhancing the durability of military and aerospace assets through non-chromate corrosion control and providing medical professionals with realistic training ecosystems for hemorrhage control. By partnering with government agencies, defense contractors, and leading industrial organizations, the company focuses on advancing research from initial discovery through to commercial-scale implementation. Their commitment to innovation is evidenced by the successful deployment of their technologies in high-stakes environments and their ongoing development of platforms intended to address complex conditions like PTSD and traumatic brain injury.
Inquire about this partnering listing
Industry applications
delivered to your inbox.